

1653
Attorney Docket No.: S0351/186588

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Patrick J. Burns

Serial No.:

09/336,328

Filed:

June 18, 1999

For:

COMPOSITIONS SUITABLE FOR
CONTROLLED RELEASE OF THE
HORMONE GNRH AND ITS
ANALOGS



Art Unit: 1653

Examiner: F. Moezie

RECEIVED
MAR 05 2001
TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with Rules 56, 97 and 98 of the Rules of Practice in Patent Cases (37 C.F.R. §§ 1.56, 1.97, and 1.98), the publications listed on the attached modified Form PTO-1449 are enclosed with this submission for consideration by the Examiner. None of the identified materials is conceded as being prior art within the meaning of the United States patent laws.

This Information Disclosure Statement is being filed before the issuance of a first office action on the merits of the application (37 C.F.R. 1.97(b)(3)); therefore, no fee is

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on this 22ND day of February 2001 with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

ATLLIB01 1112520.1

Robert B. Roberts

U.S.S.N.: 09/336,328

Filed: June 18, 1999

For: Compositions Suitable for Controlled Release of the Hormone GnRH and its Analogs
INFORMATION DISCLOSURE STATEMENT

RECEIVED

MAR 05 2001

TECH CENTER 1600/2900

believed to be due. If a fee is due, the Commissioner is authorized to charge such fee and any additional fees that may be due or credit any overpayment to Deposit Account No. 11-0855.

Respectfully submitted,



Bruce D. Gray
Reg. No. 35,799

Date: February 22, 2001

KILPATRICK STOCKTON LLP
Suite 2800, 1100 Peachtree Street
Atlanta, Georgia 30309-4530
(404) 815-6218

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 6

Complete if Known

Application Number	09/336,328
Filing Date	June 18, 1999
First Named Inventor	Patrick J. Burns
Group Art Unit	1653
Examiner Name	F. Moezie
Attorney Docket Number	S0351/186588

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		2,931,802		Toney	04/05/1960	
		3,853,837		Fujino et al.	12/10/1974	
		3,992,365		Beddell et al.	11/16/1976	
		4,024,248		Konig et al.	05/17/1977	
		4,100,274		Dutta et al.	07/11/1978	
		4,411,890		Momany	10/25/1983	
		4,530,840		Tice et al.	07/23 /1985	
		4,622,219		Haynes	11/11/1986	
		4,725,442		Haynes	02/16/1998	
		4,767,628		Hutchinson	08/30/1998	
		4,891,225		Langer	01/02/1990	
		4,906,474		Langer	03/06/1990	
		4,938,763		Dunn et al.	07/03/1990	
		4,957,744		Della Valle et al.	09/18/1990	
		5,149,543		Cohen	09/22/1992	
		5,278,201		Dunn et al.	01/11/1994	
		5,278,202		Dunn et al.	01/11/1994	
		5,324,519		Dunn et al.	06/28/1994	
		5,324,520		Dunn et al.	06/28/1994	
		5,330,835		Kikuchi et al.	07/19/1994	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		DE	1 569 231		Squibb	08/21/1969		
		JP	2096516		Dai Nippon	04/09/1990		✓
		JP	7115901		Fuji Beverage	05/09/1995		✓
		WO	95/17901	A1	Matrix Pharm.	07/06/1995		
		WO	96/39995	A1	Southern BioSystems	12/19/1996		
		WO	97/15285	A1	Axtrix Labs	05/ /1997		
		WO	91/18016	A1	Deghenghi	11/28/1991		
		WO	93/07833	A2	Peptide Tech.	04/29/1993		
		WO	98/34596	A2	3M	08/13/1998		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 6

Complete if Known

Application Number	09/336,328
Filing Date	June 18, 1999
First Named Inventor	Patrick J. Burns
Group Art Unit	1653
Examiner Name	F. Moezie
Attorney Docket Number	S0351/186588


RECEIVED

MAR 03 2001

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		5,340,572		Patel et al.	08/23/1994	
		5,340,849		Dunn et al.	08/23/1994	
		5,350,741		Takada	09/27/1994	
		5,352,662		Brooks et al.	10/04/1994	
		5,391,381		Wong et al.	02/21/1995	
		5,399,363		Liversidge et al.	03/21/1995	
		5,487,898		Lu et al.	01/30/1996	
		5,545,408		Trigg et al.	08/13/1996	
		5,569,450		Duan et al.	10/29/1996	
		5,599,552		Dunn et al.	02/04/1997	
		5,702,716		Dunn et al.	12/30/1997	
		5,725,841		Duan et al.	03/10/1998	
		5,733,950		Dunn et al.	03/31/1998	
		5,736,152		Dunn	04/07/1998	
		5,739,176		Dunn et al.	04/14/1998	
		5,747,058		Tipton et al.	05/05/1998	
		5,750,100		Yamagata et al.	05/12/1998	
		5,759,563		Yewey et al.	06/02/1998	
		5,780,044		Yewey et al.	07/14/1998	
		5,840,329		Bai	11/24/1998	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		WO	00/78335	A1	Southern Biosystems	12/28/2000		
		WO	98/27962	A2	Alza Corp.	07/02/1998		
		WO	98/27963	A2	Alza Corp.	07/02/1998		
		WO	98/53837	A1	Southern BioSystems	12/03/1998		
		EP	0 539 751	A1	Atrix Labs	05/05/1993		
		EP	0 539 751	B1	Atrix Labs	02/18/1998		
		EP	0 773 034	A1	Atrix Labs	05/14/1997		
		EP	0 537 559	B1	Atrix Labs	01/21/1998		
		EP	0 537 559	A1	Atrix Labs	04/21/1993		

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

+

+

+

+

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	3	of	6
-------	---	----	---

Application Number	09/336,328
Filing Date	June 18, 1999
First Named Inventor	Patrick J. Burns
Group Art Unit	1653
Examiner Name	F. Moezie
Attorney Docket Number	S0351/186588

[illegible][illegible]

Date Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p>		<h3 style="text-align: center;">Complete if Known</h3> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>09/336,328</td> </tr> <tr> <td>Filing Date</td> <td>June 18, 1999</td> </tr> <tr> <td>First Named Inventor</td> <td>Patrick J. Burns</td> </tr> <tr> <td>Group Art Unit</td> <td>1653</td> </tr> <tr> <td>Examiner Name</td> <td>F. Moezie</td> </tr> <tr> <td>Attorney Docket Number</td> <td>S0351/186588</td> </tr> </table>		Application Number	09/336,328	Filing Date	June 18, 1999	First Named Inventor	Patrick J. Burns	Group Art Unit	1653	Examiner Name	F. Moezie	Attorney Docket Number	S0351/186588
Application Number	09/336,328														
Filing Date	June 18, 1999														
First Named Inventor	Patrick J. Burns														
Group Art Unit	1653														
Examiner Name	F. Moezie														
Attorney Docket Number	S0351/186588														
Sheet	4	of	6												



OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		"3M DDS Announces Development of New HFA-Compatible Excipients: Novel Oligomeric Acids as MDI Suspension Aids and Solubilizers," 3M Delivery Newsletter, 3M Drug Delivery Systems, Vol. 15, June 2000	
		Ajayaghosh, A., et al., "Solid-Phase Synthesis of N-Methyl and N-Ethylamides of Peptides Using Photolytically Detachable ((3-Nitro-4-((alkylamino)methyl) benzamido)methyl)polystyrene Resin," <u>J. Org. Chem.</u> , 55:2826 (1990)	
		Barb, R. et al., "Evaluation of the Saber Delivery System for the Controlled Release of Deslorelin: Effect of Dose in Estrogen Primed Ovariectomized Gilts," <u>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.</u> , 26 (1999)	
		Becker, S.E., et al. "Effects of Gonadotropin-Releasing Hormone Infused in a Pulsatile or Continuous Fashion on Serum Gonadotropin Concentrations and Ovulation in the Mare," <u>J. Anim. Sci.</u> (1992) 70:1208-1215	
		Betschart, R., et al., "Evaluation of the Saber™ Delivery System for the Controlled Release of the GnRH Analogue Deslorelin for Advancing Ovulation in Mares: Effect of Gamma Radiation," <u>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.</u> 25 (1998) Controlled Release Society, Inc. pp. 655-656	
		Bühler, K., "GnRH Agonists and Safety, In GnRH Analogues The State of the Art 1993, A Summary of the 3rd International Symposium on GnRH Analogues in Cancer and Human Reproduction, Geneva, February 1993	
		Burns, P. et al., "Pharmacodynamic Evaluation of the Saber™ Delivery System for the Controlled Release of the GnRH Analogue Deslorelin Acetate for Advancing Ovulation in Cyclic Mares," <u>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.</u> , 24 (1997), Controlled Release Society, Inc.	
		Coy, et al., "Solid Phase Synthesis of Lutcinizing Hormone-Releasing Hormone and Its Analogs," <u>Methods Enzymol.</u> 37, 416 (1975)	
		Desai, Neil P., et al. "Surface Modifications of Polymeric Biomaterials for Reduced Thrombogenicity," <u>Polymeric Materials Science and Engineering</u> , Vol. 62, 1990 by ACS	
		Duan, D. et al., "Novel Dispersing Aids for Hydrofluoroalkane-Based Metered Dose Inhalers," 1998 Conference of the American Association of Pharmaceutical Scientists, San Francisco, California, November 1998	
		Duan, D. et al., "Oligomeric Lactic Acids as Solubilizing Aids for HFA-Based Metered Dose Inhalers," 1998 Conference of the American Association of Pharmaceutical Scientists, San Francisco, California, November 1998	
		Fitzgerald, B.P. et al., "Effect of Constant Administration of a Gonadotropin-Releasing Hormone Agonist on Reproductive Activity in Mares: Preliminary Evidence on Suppression of Ovulation During the Breeding Season," <u>Am. J. Vet. Res.</u> , 54:10 1746-	
		Fleury, J., et al. "Evaluation of the Saber™ Delivery System for the Controlled Release of the Deslorelin for Advancing Ovulation in the Mare: Effects of Formulation & Dose," <u>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.</u> 25 (1998) Controlled Release Society, Inc. pp. 657-658	
		Ginter, O.J., "Reproductive Biology of the Mare: Basic and Applied Aspects, <u>EquiServices</u> , Chapter 12, 499-508 Cross Plains, Wisconsin (1970)	
		Ginter, O.J. et al. "Effect of a Synthetic Gonadotropin-Releasing Hormone on Plasma Concentrations of Lutcinizing Hormone in Ponies," <u>Am. J. Vet. Res.</u> , 35: 79-81 (1974)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet		5	of	6	Application Number 09/336,328
					Filing Date June 18, 1999
					First Named Inventor Patrick J. Burns
					Group Art Unit 1653
					Examiner Name F. Moezie
					Attorney Docket Number S0351/186588



OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Ginther, O.J., "Ultrasonic Imaging and Reproductive Events in the Mare," <u>Equiservices</u> , Cross Plains, WI Chapter 4: 43-72 (1986)	
		Harrison, L., <i>et al.</i> "Comparison of HCG, Buserelin and Luprostiol for Induction of Ovulation in Cycling Mares," <u>J. Eq. Vet. Sci.</u> , 11:163-166 (1991)	
		Henry, C. "Sucrose Acetate Isobutyrate Special Grade for Beverage Applications"	
		Hyland, J.H., <i>et al.</i> "Infusion of Gonadotrophin-Releasing Hormone (GnRH) Induces of Ovulation and Fertile Oestrus in Mares During Seasonal Anoestrus," <u>J. Reprod. Fert.</u> , Suppl. 35 (1987), 211-220	
		Irvine, C.H. G., "GnRH Clinical Application," In <u>Equine Reproduction</u> , (eds) McKinnon, A.O. and Voss, J.L., Chapter 36, pp. 41-45, Lea & Febiger (1993)	
		Irvine, D.S., <i>et al.</i> , "Duration of Oestrus and Time of Ovulation in Mares Treated with Synthetic GnRH (Ay24,031)," <u>J. Reprod. Fert. Supp.</u> , 23:279-283 (1975)	
		Jochle, W., <i>et al.</i> , "Control of Ovulation in the Mare with Ovuplant™, a Short-Term Release Implant (STI) Containing the GNRH Analogue Deslorelin Acetate: <u>J. Eq. Vet. Sci.</u> , 44:632 (1994)	
		Kulkarni <i>et al.</i> , "Polyactic Acid for Surgical Implants," <u>Arch. Surg.</u> , 93:389 (1966)	
		LaCoste, D., <i>et al.</i> , "Reversible Inhibition of Testicular Androgen Secretion by 3-, 5- and 6-Month Controlled-Release Microsphere Formulations of the LH-RH Agonist [D-Trp ⁶ , des-Gly-NH ₂ ¹⁰] LH-RH Ethylamide in the Dog," <u>J. Steroid Biochem.</u> , 33:5, 1007-1011 (1989)	
		Loy, R.G. <i>et al.</i> "The Effects of Human Chorionic Gonadotrophin on Ovulation, Length of Estrus, and Fertility in the Mare," <u>Cornell Vet.</u> , 56:41-50 (1966)	
		Material Safety Data Sheet of Eastman Chemical Products, "SAIB" Sucrose Acetate Isobutyrate," pp. 2-18	
		Material Safety Data Sheet of Eastman Fine Chemical Pharmaceutical Ingredients, "Sucrose Acetate Isobutyrate Special Grade (SAIB-SG), Publication No. EFC-211, (May 1991)	
		Material Safety Data Sheet of Eastman Products for the Food Industry, "Sucrose Acetate Isobutyrate (SAIB-SG) for Use in Fruit-Flavored Beverages," Publication No. ZM-90, pp. 2-7 (Sept. 1989)	
		Meams, "Changing Seasons," <u>The Blood-Horse</u> , Sept. 28, 1996, p. 4794-4795	

Examiner Signature	Date Considered
-----------------------	--------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 10px 0;">(use as many sheets as necessary)</p>			Complete if Known		
			Application Number	09/336,328	
			Filing Date	June 18, 1999	
			First Named Inventor	Patrick J. Burns	
			Group Art Unit	1653	
			Examiner Name	F. Moezie	
			Attorney Docket Number	S0351/186588	
Sheet	6	of	6		



		McCarthy, P. <i>et al.</i> , "Management of Stallions on Large Breeding Farms," <u>Stallion Management</u> , Vol. 8, No. 1, April 1992, pp. 219-235	
		McKinnon, A.O., <i>et al.</i> , "Effect of a GnRH Analogue (Ovuplant), hCG and Dexamethasone on Time to Ovulation in Cycling Mares," <u>World Equine Veterinary Review</u> , (1997) 2:3 16-18	
		McKinnon, A.O., <i>et al.</i> , "Repeated Use of a GnRH Analogue Deslorelin (Ovuplant) for Hastening Ovulation in the Transitional Mare," <u>Equine Vet. J.</u> , (1996) 29:2 153-155	
		Merrifield, B., <u>Science</u> 232:342 (1986)	
		Montovan, S.M., <i>et al.</i> , "The Effect of a Potent GnRH Agonist on Gonadal and Sexual Activity in the Horse," <u>Theriogenology</u> , 33:6, 1305-1321 (1990)	
		Mumford, E.L. <i>et al.</i> , "Use of Deslorelin Short-Term Implants to Induce Ovulation in Cycling Mares During Three Consecutive Estrovs Cycles," <u>Animal Reproduction Science</u> , 139 (1995) 129-140	
		Nett <i>et al.</i> , "Further Studies on the Radioimmunoassay of Gonadotropin-Releasing Hormone: Effect of Radioiodination, Antiserum and Unextracted Serum on Levels of Immunoreactivity in Serum," <u>Endocrinology</u> 101: 1135 (1977)	
		Rabb <i>et al.</i> , "Effects of Active Immunization Against GnRH on LH, FSH and Prolactin Storage, Secretion and Response to Their Secretagogues in Pony Geldings," <u>J. Anim. Sci.</u> , 68: 3322-3329 (1990)	
		Roser, J.J., <i>et al.</i> , "The Development of Antibodies to Human Chorionic Gonadotropins Following its Repeated Injection in the Cyclic Mare," <u>J. Reprod. Fert. Suppl.</u> , 173-179 (1979)	
		Sullivan, J., "Duration of Estrus and Ovulation Time in Nonlactating Mares Given Human Chorionic Gonadotropin During Three Successive Estrous Periods," <u>J. Am. Vet. Med. Assoc.</u> , 63:895 (1973)	
		Thompson, Jr., D.L., <i>et al.</i> , "Effects of Melatonin and Thyrotropin Releasing Hormone of Mares During the Nonbreeding Season," <u>J. Anim. Sci.</u> , 58:3, 668-677(1983)	
		Thompson, Jr., D.L., <i>et al.</i> , "Testosterone Effects on Mares During Synchronization with Altrenogest: FSH, LH, Estrous, Duration and Pregnancy Rate," <u>J. Anim. Sci.</u> , 56:3, 678-686 (1983)	
		Voss, J.L., <i>et al.</i> , "The Effect of HCG on Duration of Oestrus, Ovulation Time and Fertility in Mares," <u>J. Reprod. Fert., Suppl.</u> 23 (1975) 297-301	

Examiner Signature	Date Considered
-----------------------	--------------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.